immuneGlobe

Executive Summary

immuneGlobe GmbH is a Munich-based antibody service provider specializing in the production of high-quality polyclonal rabbit antibodies against challenging targets such as point mutations, isoforms, and post-translational modifications. Founded in 2020, the company differentiates itself by achieving monoclonal-like specificity with polyclonal reagents through sophisticated immunization, purification, and depletion strategies. immuneGlobe serves as a direct manufacturer, offering custom antibody development services to researchers and biopharma clients. While the company operates in a competitive antibody market, its unique technical approach and focus on customized solutions position it as a niche player. However, limited public information on revenue, funding, or commercial partnerships constrains visibility into its growth trajectory and market traction.

Upcoming Catalysts (preview)

• Q3 2026Launch of new polyclonal antibody line for post-translational modifications60% success
• Q4 2026Securing a collaboration agreement with a mid-tier biopharma company40% success
• Q1 2026Receipt of innovation grant or government funding for antibody platform development70% success